Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance

Table 3 Association between pancreatic adenocarcinoma upregulated factor expression and clinicopathological features of pancreatic cancer patients

Clinicopathological features	Low group (%)	High group (%)	P value	95%CI
Age (years)			0.6217	0.46-3.7
< 60	33.3	66.7
≥ 60	27.8	72.2
Sex			0.8245	0.37-2.2
Male	27.9	72.1
Female	30.0	70.0
Tumor location			0.8942	0.39-3.0
Head	29.4	70.6
Body or tail	28.0	72.0
Stage			0.46	0.26-1.8
RPC	26.9	73.1
BRPC	34.6	65.4
Lymph node			0.0019b	1.7-14
Negative	57.9	42.1
Positive	21.6	78.4
RM			0.2707	0.64-4.71
Negative	32.8	67.2
Positive	21.9	78.1
Adjuvant therapy			0.3347	0.63-3.83
None	34.1	65.9
Yes	25.0	75.0
CA 19-9			0.0842	0.89-5.75
< 150 U/mL	36.7	63.3
≥ 150 U/mL	20.5	79.5
Histology			0.4122	0.20-1.93
WD/MD/others	37.5	62.5
PD: 27.3	72.7

^bP < 0.01 vs lymph node-negative group.

RPC: Resectable pancreatic cancer; BRPC: Borderline resectable pancreatic cancer; RM: Resection margin; CA 19-9: Carbohydrate antigen 19-9; PD: Poorly differentiated; WD: Well differentiated; MD: Moderately differentiated; CI: Confidence interval.